Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

229 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124

Conditions
Bladder Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 0043) Phoenix, Arizona, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0035) Fullerton, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005) Los Angeles, California, United States
  • University of California San Francisco ( Site 0010) San Francisco, California, United States
View all 188 locations
View Trial Details
Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +13 more
Locations
  • Research Site Chicago, Illinois, United States
  • Research Site Rochester, Minnesota, United States
  • Research Site Fairfax, Virginia, United States
  • Research Site Melbourne, Australia
View all 40 locations
View Trial Details
Active, not recruiting

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations
  • City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) Duarte, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro Los Angeles, California, United States
  • UCSF Medical Center at Mission Bay ( Site 0108) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) New Haven, Connecticut, United States
View all 63 locations
View Trial Details
Active, not recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722

Conditions
Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +10 more
Locations
  • Mid Florida Cancer Center ( Site 1519) Orange City, Florida, United States
  • University Cancer & Blood Center, LLC ( Site 1521) Athens, Georgia, United States
  • University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P Chicago, Illinois, United States
  • Icahn School of Medicine at Mount Sinai ( Site 1528) New York, United States
View all 109 locations
View Trial Details
Active, not recruiting

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

NCT04938817

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more
Locations
  • Banner MD Anderson Cancer Center ( Site 0152) Gilbert, Arizona, United States
  • Northside Hospital-Northside Hospital Oncology Network ( Site 0156) Atlanta, Georgia, United States
  • Parkview Research Center at Parkview Regional Medical Center ( Site 0180) Fort Wayne, Indiana, United States
  • Baptist Health Lexington-Research ( Site 0158) Lexington, Kentucky, United States
View all 48 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
Locations
  • Beijing Cancer hospital-Digestive Oncology ( Site 0001) Beijing, Beijing Municipality, China
  • Beijing Peking Union Medical College Hospital-Medical Oncology ( Site 0011) Beijing, Beijing Municipality, China
  • Tianjin Medical University Cancer Institute and Hospital-Gastric oncology ( Site 0019) Tianjin, Beijing Municipality, China
  • The First Affiliated Hospital of Chongqing Medical University ( Site 0051) Chongqing, Chongqing Municipality, China
View all 32 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • University of South Alabama, Mitchell Cancer Institute ( Site 0003) Mobile, Alabama, United States
  • St. Bernards Medical Center ( Site 0089) Jonesboro, Arkansas, United States
  • St Joseph Heritage Healthcare-Oncology ( Site 0088) Fullerton, California, United States
  • Long Beach Memorial Medical Center ( Site 0006) Long Beach, California, United States
View all 205 locations
View Trial Details
Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Mayo Clinic in Arizona - Phoenix ( Site 3554) Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center ( Site 3567) Duarte, California, United States
  • Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516) La Jolla, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520) Los Angeles, California, United States
View all 285 locations
View Trial Details
Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +10 more
Locations
  • HonorHealth-USOR HonorHealth ( Site 8000) Phoenix, Arizona, United States
  • Moores Cancer Center ( Site 0037) La Jolla, California, United States
  • Kaiser Permanente Riverside Medical Center ( Site 0045) Riverside, California, United States
  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013) New Haven, Connecticut, United States
View all 194 locations
View Trial Details
Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032

Conditions
High-Risk Non-Muscle Invasive Bladder Cancer, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Alaska Urological Institute dba Alaska Clinical Research Center ( Site 1083) Anchorage, Alaska, United States
  • Mayo Clinic in Arizona - Phoenix ( Site 1094) Phoenix, Arizona, United States
  • Del Sol Research Management, LLC ( Site 1096) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 1052) Los Angeles, California, United States
View all 209 locations
View Trial Details

Related conditions